The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorSezer, Atakan
dc.contributor.authorUsta, Ufuk
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T11:13:48Z
dc.date.available2024-06-12T11:13:48Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractTo investigate the efficiency of Saccharomyces boulardii on irinotecan-induced mucosal damage and diarrhea in rats, fifty rats were randomized into three groups with 20 rats in two study groups and 10 rats in the control group. Control group did not receive any treatment. Irinotecan (60 mg/kg) alone was administered intravenously once a day for four consecutive days to the rats of Group A. Throughout the experiment, Group B rats were additionally given Saccharomyces boulardii (800 mg/kg) for 3 days before administration of irinotecan and 7 days throughout the experiment. Delayed diarrhea was more severe in Group A than Group B (P = 0.009). The weight loss was 34.7 +/- A 3.8 mg for Group A, while it was 17.4 +/- A 1.7 mg for Group B (P < 0.001). Findings of mucositis most clearly appeared in the jejunum. Regarding edema (P = 0.003), leukocyte migration (P = 0.038), and inflammation (P = 0.006) significant recovery was detected in the mucosa of rats receiving Saccharomyces boulardii. Villous thickness was significantly greater in Group A than Group B (P < 0.001). The results indicate that Saccharomyces boulardii provided significant improvement in irinotecan-induced diarrhea and mucositis.en_US
dc.identifier.doi10.1007/s12032-008-9128-1
dc.identifier.endpage357en_US
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue3en_US
dc.identifier.pmid19067257en_US
dc.identifier.scopus2-s2.0-77952653193en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage350en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-008-9128-1
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23688
dc.identifier.volume26en_US
dc.identifier.wosWOS:000269118000016en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSaccharomyces Boulardiien_US
dc.subjectIrinotecanen_US
dc.subjectDiarrheaen_US
dc.subjectMucositisen_US
dc.subjectClostridium-Difficile Diseaseen_US
dc.subjectPlacebo-Controlled Trialen_US
dc.subjectInfected T84 Cellsen_US
dc.subjectPhase-Iien_US
dc.subjectT-Cellsen_US
dc.subjectToxin-Aen_US
dc.subjectCanceren_US
dc.subjectRaten_US
dc.subjectPreventionen_US
dc.subjectDamageen_US
dc.titleThe effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrheaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu